Keep Current with the Latest in Cell Biology Research

Adducin Regulates Sarcomere Disassembly During Cardiomyocyte Mitosis

[Circulation] Researchers used a proteomics screen to identify adducin, an actin capping protein previously not studied in cardiomyocytes, as a regulator of sarcomere disassembly.

Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury

[Circulation] Scientists studied the function of homeobox-containing 1 (Hmbox1) in exercise-induced physiological cardiac growth in mice after four weeks of swimming exercise. Hmbox1 expression was then evaluated in human heart samples from deceased patients with myocardial infarction and in the animal cardiac ischemia/reperfusion injury model.

Use of iPSC-Derived Smooth Muscle Cells to Model Physiology and Pathology

[Arteriosclerosis Thrombosis And Vascular Biology] Challenges both specific, e.g. the lack of specific markers to thoroughly validate human induced pluripotent stem cell-smooth muscle cells (hiPSC-SMC), and general, e.g. a lack of transparency and consensus around methodology in the field, remain. Scientists highlight the recent successes and remaining challenges of the hiPSC-SMC model.

Heart Disease Research in Doberman Patient Replaces Animal Experiments

[Utrecht University] A team of researchers from Utrecht University and UMC Utrecht has received a grant of 936,587 euros from the ZonMw Open Competition for research into a serious heart condition that affects both humans and dogs, especially Dobermanns.

TFPI from Erythroblasts Drives Heme Production in Central Macrophages Promoting Erythropoiesis in Polycythemia

[Nature Communications] Investigators discovered that an anticoagulant protein tissue factor pathway inhibitor (TFPI) played an essential role in erythropoiesis via the control of heme biosynthesis in central macrophages.

Bone Mesenchymal Stem Cells Improve Cholestatic Liver Fibrosis by Targeting ULK1 to Regulate Autophagy through PI3K/AKT/mTOR Pathway

[Stem Cells Translational Medicine] Scientists investigated the therapeutic effects and underlying mechanisms of bone MSCs transplantation in mouse models of bile duct ligation-induced cholestatic liver fibrosis.

Regulation of Myc Transcription by an Enhancer Cluster Dedicated to Pluripotency and Early Embryonic Expression

[Nature Communications] Researchers used genomic rearrangements, transgenesis, and targeted mutation to analyze Myc regulation in early mouse embryos and PSCs.

Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

[Targeted Oncology] Kristen Rat Sarcoma viral oncogene (KRAS) mutations are one of the most common oncogenic drivers found in 12–14% of NSCLC and 4% of colorectal cancer tumors.

Dickkopf-1 (DKK1) Drives Growth and Metastases in Castration-Resistant Prostate Cancer

[Cancer Gene Therapy] The authors investigated the role of the Wnt signaling modulator Dickkopf-1 (DKK1) in the growth and metastatic progression of metastatic CRPC.

Twist2 Contributes to Skin Regeneration and Hair Follicle Formation in Mouse Fetuses

[Scientific Reports] Scientists elucidated Twist2 expression and its role in fetal wound healing. Mouse fetuses were surgically wounded, and Twist2 expression in tissue samples from these fetuses were evaluated via in situ hybridization, immunohistochemistry, and reverse transcription-quantitative polymerase chain reaction.

The Janus Kinase 1 Is Critical for Pancreatic Cancer Initiation and Progression

[Cell Reports] Using a ligand-controlled and pancreas-specific knockout in adult mice, researchers demonstrated that Janus tyrosine kinase (JAK1) deficiency prevented the formation of KRASG12D-induced pancreatic tumors. They established that JAK1 was essential for the constitutive activation of STAT3, whose activation is a prominent characteristic of PDAC.

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

[Oncolytics Biotech, Inc.] Oncolytics Biotech® Inc. will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX with or without the PD-L1 immune checkpoint inhibitor atezolizumab in newly diagnosed patients with PDAC.

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

spot_img